Novartis COPD drug approved in the US, Japan

In separate announcements, Novartis AG said that its bronchodilator for chronic obstructive pulmonary disease, indacaterol, has been approved by regulatory authorities in the US and Japan. The drug is a long-acting beta2-agonist.